...
首页> 外文期刊>European review for medical and pharmacological sciences. >MicroRNA-646 inhibits proliferation and cell cycle progression of nasopharyngeal carcinoma cells by targeting mTOR
【24h】

MicroRNA-646 inhibits proliferation and cell cycle progression of nasopharyngeal carcinoma cells by targeting mTOR

机译:MicroRNA-646通过靶向MTOR抑制鼻咽癌细胞的增殖和细胞周期进展

获取原文
           

摘要

OBJECTIVE: To clarify whether microRNA-646 could regulate the proliferative potential and cell cycle progression of nasopharyngeal carcinoma cells through targeting mammalian target of rapamycin (mTOR). It, therefore, could influence the occurrence and progression of nasopharyngeal carcinoma. PATIENTS AND METHODS: Quantitative Real-time polymerase chain reaction (qRT-PCR) was used to detect expression of the levels of microRNA-646 and mTOR in tumor tissues and paracancerous tissues of patients with nasopharyngeal carcinoma. Besides, their expressions in nasopharyngeal carcinoma cell lines were determined by qRT-PCR. Survival analysis was conducted to evaluate the sensitivity and specificity of microRNA-646 in diagnosing nasopharyngeal carcinoma. The overall survival of patients with nasopharyngeal carcinoma was calculated based on their expression levels of microRNA-646. The regulatory effects of microRNA-646 and mTOR on proliferative potential and cell cycle progression were explored by cell counting kit-8 (CCK-8) assay and flow cytometry, respectively. Dual-luciferase reporter gene assay was conducted to verify the relationship between microRNA-646 and mTOR, which was further confirmed by Pearson correlation analysis. Finally, gain-of-function experiments were carried out to determine whether microRNA-646 could regulate the proliferative potential and cell cycle progression of nasopharyngeal carcinoma cells by targeting mTOR. RESULTS: MicroRNA-646 was lowly expressed in nasopharyngeal carcinoma tissues and cell lines. Survival analysis confirmed the diagnostic value of microRNA-646 in nasopharyngeal carcinoma. Besides, the nasopharyngeal carcinoma patients with high level of microRNA-646 were expected to have a longer 5-year survival time compared with those with low level. Overexpression of microRNA-646 inhibited the proliferative potential and cell cycle progression of HONE1 and SUNE1 nasopharyngeal carcinoma cells. Dual-luciferase reporter gene assay detected the binding of microRNA-646 to mTOR. Moreover, mTOR was highly expressed in nasopharyngeal carcinoma tissues and cell lines. A negative correlation was found between microRNA-646 and mTOR. That is, the overexpression of mTOR could reverse the inhibitory effects of microRNA-646 on the proliferative potential and cell cycle progression of HONE1 and SUNE1 cells. CONCLUSIONS: MicroRNA-646 remains a low level in nasopharyngeal carcinoma. It inhibits the proliferative potential and cell cycle progression of nasopharyngeal carcinoma cells by targeting mTOR. It can, therefore, inhibit the development of nasopharyngeal carcinoma.
机译:目的:阐明MicroRNA-646是否可以通过靶向哺乳动物催乳素(MTOR)调节鼻咽癌细胞的增殖潜力和细胞周期进展。因此,它可能影响鼻咽癌的发生和进展。患者和方法:使用定量实时聚合酶链反应(QRT-PCR)检测鼻咽癌肿瘤组织中MicroRNA-646和MTOR水平的表达和鼻咽癌患者的副血管组织。此外,它们在鼻咽癌细胞系中的表达由QRT-PCR测定。进行存活分析以评估MicroRNA-646在诊断鼻咽癌方面的敏感性和特异性。基于其MicroRNA-646的表达水平计算鼻咽癌患者的整体存活。通过细胞计数试剂盒-8(CCK-8)测定和流式细胞术分别探讨了MicroRNA-646和MTOR对增殖潜力和细胞周期进展的调节作用。进行双荧光素酶报告基因测定以验证MicroRNA-646和MTOR之间的关系,该关系是通过Pearson相关分析进一步证实的。最后,进行了函数的实验,以确定MicroRNA-646是否可以通过靶向MTOR调节鼻咽癌细胞的增殖潜力和细胞周期进展。结果:MicroRNA-646在鼻咽癌组织和细胞系中低于表达。存活分析证实了MicroRNA-646在鼻咽癌中的诊断值。此外,预期鼻咽癌患者高水平的microRNA-646的患者与低水平的人相比,预期具有较长的5年生存时间。 MicroRNA-646的过表达抑制了河内1和Sune1鼻咽癌细胞的增殖性潜力和细胞周期进展。双荧光素酶报告酶基因测定检测到MicroRNA-646至MTOR的结合。此外,MTOR在鼻咽癌组织和细胞系中高度表达。在MicroRNA-646和MTOR之间发现了负相关。也就是说,MTOR的过表达可以逆转MicroRNA-646对河内和SUNE1细胞增殖潜力和细胞周期进展的抑制作用。结论:MicroRNA-646在鼻咽癌中仍然是低水平。通过靶向MTOR抑制鼻咽癌细胞的增殖潜力和细胞周期进展。因此,它可以抑制鼻咽癌的发展。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号